Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Amortization of Deferred Charges (2020 - 2022)

Historic Amortization of Deferred Charges for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Q3 2022 value amounting to $1000.0.

  • Insight Molecular Diagnostics' Amortization of Deferred Charges fell 9230.77% to $1000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $12000.0, marking a year-over-year decrease of 7857.14%. This contributed to the annual value of $12000.0 for FY2022, which is 7857.14% down from last year.
  • According to the latest figures from Q3 2022, Insight Molecular Diagnostics' Amortization of Deferred Charges is $1000.0, which was down 9230.77% from $4000.0 recorded in Q2 2022.
  • In the past 5 years, Insight Molecular Diagnostics' Amortization of Deferred Charges registered a high of $35000.0 during Q1 2020, and its lowest value of $1000.0 during Q3 2022.
  • Its 3-year average for Amortization of Deferred Charges is $15454.5, with a median of $14000.0 in 2021.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Amortization of Deferred Charges plummeted by 3636.36% in 2021, and later plummeted by 9230.77% in 2022.
  • Over the past 3 years, Insight Molecular Diagnostics' Amortization of Deferred Charges (Quarter) stood at $22000.0 in 2020, then plummeted by 54.55% to $10000.0 in 2021, then plummeted by 90.0% to $1000.0 in 2022.
  • Its Amortization of Deferred Charges stands at $1000.0 for Q3 2022, versus $4000.0 for Q2 2022 and $7000.0 for Q1 2022.